Beta methylphenethylalamine

Synopsis

Beta-Methylphenethylamine (BMPEA): A Comprehensive Reference

1. Identity

Chemical Names and Synonyms

β-Methylphenethylamine (β-Me-PEA, BMPEA, or 1-amino-2-phenylpropane) is an organic compound of the phenethylamine class, and a positional isomer of the drug amphetamine, with which it shares some properties. Structurally, it features a phenyl ring attached to a propyl chain with the amine group at the terminal position and a methyl substituent at the beta carbon relative to the amine, and shares the molecular formula C₉H₁₃N with amphetamine.

The compound is known under a large number of synonyms and variant spellings. These include: 1-Amino-2-Phenylpropane, 1-Phenyl-1-Methyl-2-Aminoethane, 2-Aminoisopropylbenzene, 2-Phenyl-1-Propanamine, 2-Phenylpropylamine, Alpha-Benzylethylamine, ß-Me-PEA, Beta-Me-PEA, Beta-Methylbenzeneethanamine, Beta-Methylphenylethylamine, Beta-Methylphenylethylamine HCl, BMPEA, Beta-Phenylpropylamine, R-Beta-Methylphenethylamine, and R-Beta-Methylphenethylamine HCl. The abbreviation BMPEA is the most widely used in the scientific and regulatory literature.

Physical Appearance and Synthesis

In appearance, BMPEA is a colorless or yellowish liquid. It can be made by the catalytic hydrogenation of 2-phenylpropionitrile with Pd/C in pure anhydrous ethanol containing three equivalents of HCl; the finished product is extracted as the HCl salt with a melting point of 123–124°C.

Natural Source Status and the Acacia rigidula Question

Preworkout supplements that list the Southwestern scrub plant Acacia rigidula as an ingredient often contain BMPEA (2-phenylpropan-1-amine), a structural isomer of amphetamine (1-phenylpropan-2-amine). The phenomenon of unlisted or misrepresented ingredients is well established for supplements promoted for bodybuilding and performance enhancement.

BMPEA was first described in the 1930s as a sympathomimetic agent. While the manufacturers of preworkout supplements claim that Acacia rigidula is a natural source of BMPEA, there is no evidence to support this assertion. Extracts of Acacia rigidula leaves are used in weight-loss products sold in vitamin shops and over the internet with little or no published data about their potential biological effects. In FDA-commissioned chemical investigations on authenticated A. rigidula plant material, a rapid and sensitive LC-MS/MS method was established for the quantitative determination of several phenethylamine, tyramine, and tryptamine derivatives using stable isotopically labeled compounds as internal standards, finding total calculated contents of six biogenic amines in A. rigidula leaf of 18.6 and 32.9 μg/g.

The content of selected amines in 21 dietary supplements labeled as containing A. rigidula was determined by a second LC-MS/MS method. The study revealed significant differences in the amine profiles of authenticated plant materials and dietary supplements. β-Methylphenethylamine, described as a non-natural compound, was found in 9 of the 21 dietary supplement products.

Research conducted by the US Food and Drug Administration (FDA) in 2013 established that BMPEA is not a constituent or extract of A. rigidula. BMPEA is not found naturally in Acacia rigidula or any other known plants. Any dietary supplement products containing BMPEA are considered misbranded by the US FDA.

Common Forms and Preparations

BMPEA is a synthetic compound structurally related to phenethylamine and has gained attention as an ingredient in various nutritional supplements, particularly those marketed for energy, weight loss, or cognitive enhancement. Many of these supplements list Acacia rigidula on the product label, but many of these products do not contain Acacia rigidula, and if they do, BMPEA that was made in a laboratory has been added as well. It is found in capsule and powder forms, typically marketed as pre-workout or weight-loss products. The hydrochloride salt (BMPEA HCl) is the most commonly encountered chemical form in analytical testing of supplements.

2. Historical and Early Research Background

First Synthesis and Early Pharmacological Investigation

Historically, phenethylamine and its derivatives have been studied for their potential stimulant and mood-enhancing effects, tracing back to early research in the mid-20th century. BMPEA itself was first synthesized in the 1930s and investigated as a potential therapeutic agent, although it did not become a mainstream pharmaceutical. BMPEA was first made in the 1930s as a possible replacement to amphetamine (a central nervous system stimulant), although it never became a drug because no studies were performed on its safety in humans.

Hartung and Munch, writing in 1931, reported that BMPEA had good antihypotensive (pressor) activity in experimental animals and that it was orally active. The minimum lethal dose (MLD) for the HCl salt was given as 500 mg/kg (rat, subcutaneous) and 50 mg/kg (rabbit, intravenous). A study by Graham and co-workers at the Upjohn Co., comparing many β-methylphenethylamines substituted on the benzene ring, showed that β-methylphenethylamine itself had 1/700 × the pressor activity of epinephrine, corresponding to approximately 1/3 the potency of amphetamine.

Tests on dogs and cats from the 1930s and 1940s found increased blood pressure and heart rates after BMPEA exposure. Despite this early work, BMPEA was never advanced into formal human clinical trials and remained largely unstudied until the dietary supplement adulteration investigations of the 2010s.

Emergence in the Dietary Supplement Market

In recent years, BMPEA has been identified in some over-the-counter supplement products, often as an undeclared ingredient or as a purported natural extract of Acacia rigidula, despite limited evidence supporting its natural occurrence in plants. The compound came to wide regulatory and public health attention primarily between 2013 and 2015, when both FDA scientists and independent academic researchers published analyses of supplement adulteration.

There is no documented tradition of deliberate human use of BMPEA predating the modern dietary supplement era. Relatively little information has been published about this substance in the broader pharmacological or ethnobotanical literature, and no historical use within any recognized ethnobotanical or medical tradition has been established in peer-reviewed sources.

3. Chemical Classification and Structural Relationships

BMPEA belongs to the phenethylamine chemical class, a broad family of compounds that includes endogenous neurotransmitters (dopamine, norepinephrine, epinephrine), trace amines (phenethylamine itself), and numerous synthetic stimulants including amphetamine and methamphetamine. As a structural isomer of amphetamine (1-phenylpropan-2-amine), BMPEA (2-phenylpropan-1-amine) differs from amphetamine only in the position of the amine group on the propyl side chain. In amphetamine, the amine is at the alpha (α) carbon; in BMPEA, it is at the beta (β) carbon — hence the common name "beta-methylphenethylamine."

β-Methylphenethylamine was found in supplements at levels of 960–60,500 μg/g. It is a positional isomer of amphetamine, and research has shown that it can be misidentified as amphetamine during LC-MS analysis alone. An independent GC-MS analysis was used to confirm the presence of β-methylphenethylamine and the absence of amphetamine in dietary supplements labeled as containing A. rigidula, demonstrating that confirmations by independent analytical methods are essential to verify findings of unusual or unexpected compounds in dietary supplements.

4. Key Constituents / Active Compound and Mechanisms of Action

BMPEA itself is the sole active entity of interest; it is a single, synthetically produced molecule rather than a botanical extract with multiple phytochemical constituents.

TAAR1 Agonism

β-Methylphenethylamine is an organic compound of the phenethylamine class and a positional isomer of amphetamine. In particular, both amphetamine and β-methylphenethylamine are human TAAR1 agonists. TAAR1 (Trace Amine-Associated Receptor 1) is a G protein–coupled receptor expressed in monoaminergic neurons that plays a central modulatory role in catecholaminergic signaling. A β-methyl substituent on the phenylethylamine side chain was well tolerated at human TAAR1; indeed, S-(–)-β-methyl-β-PEA was found to be as potent as β-PEA itself at human TAAR1.

Monoamine Transporter Substrate Activity (DAT and NET)

Amphetamine and methamphetamine are potent substrate-type releasing agents at dopamine transporters (DATs) and norepinephrine transporters (NETs) in rat brain synaptosomes. BMPEA and MPPA were also substrates at DATs and NETs, but they were at least 10-fold less potent than amphetamine.

Like amphetamine, BMPEA was a releaser at DAT (EC₅₀ = 627 nM) and NET (EC₅₀ = 125 nM). In general, the transmitter-releasing actions of BMPEA analogs were more potent at NET than DAT. This NET selectivity has direct mechanistic implications: by preferentially triggering norepinephrine release via peripheral NET activity, BMPEA primarily drives cardiovascular pressor effects rather than central dopaminergic reward circuitry effects.

All three PEA analogs (BMPEA, AEPEA, and DEPEA) act as substrate-type releasers at the rat norepinephrine transporter (NET), leading to increases in blood pressure and heart rate. The PEA compounds are about 10-fold less potent than amphetamine at stimulating cardiovascular parameters. Rickli et al. (2019) confirmed that BMPEA interacts with human NET expressed in transfected cells.

Cardiovascular Mechanism: Peripheral vs. Central

A pivotal 2019 study by Schindler, Thorndike, Rice, Partilla, and Baumann at the National Institute on Drug Abuse (NIDA), published in the Journal of Pharmacology and Experimental Therapeutics, directly investigated the cardiovascular mechanism. Amphetamine (0.3–3.0 mg/kg, sc) produced significant dose-related increases in blood pressure, heart rate, and activity. By contrast, BMPEA, MPPA, and DMPPA (3.0 and 30 mg/kg, sc) produced significant increases in blood pressure but failed to clearly affect heart rate or activity. The hypertensive effect of BMPEA was reversed by pretreatment with the α-adrenergic antagonist prazosin.

The hypertensive effect of BMPEA was reversed by the α-adrenergic antagonist prazosin but not the ganglionic blocker chlorisondamine. Radioligand binding at various G protein–coupled receptors did not identify nontransporter sites of action that could account for cardiovascular effects of BMPEA or its analogs. The reversal by prazosin (which blocks post-synaptic α1-adrenergic receptors) but not by chlorisondamine (which blocks autonomic ganglia) indicates a peripheral mechanism of action mediated by local norepinephrine release at vascular tissue, rather than central nervous system activation of the sympathetic axis.

Results show that BMPEA, MPPA, and DMPPA are biologically active. The compounds are unlikely to be abused due to weak effects at DATs, but they could produce adverse cardiovascular effects via substrate activity at peripheral NET sites.

Adrenergic Receptor Interactions

Phenethylamines (PEAs) and alkylamines are widely present in dietary supplements. Although the health effects of these analogues are not well understood, they are hypothesized to be agonists of adrenergic (ADR) and trace amine-associated receptors (TAARs). Research has aimed to pharmacologically characterize these compounds by investigating their activating properties of ADRs and TAAR1 in vitro. Multiple PEAs activated ADRs (EC₅₀ = 34 nM–690 µM; Emax = 8–105%). Almost all PEAs activated TAAR1 (EC₅₀ = 1.8–92 µM; Emax = 40–104%).

BMPEA had mid-nanomolar affinities at subtypes of α2-adrenoreceptors, sites that can modulate blood pressure. However, the fact that MPPA had equal or greater effects on blood pressure than BMPEA but was inactive at α2-adrenoreceptor subtypes appears to rule out a dominant role for these sites in the blood pressure changes observed.

Locomotor and Behavioral Effects in Animals

BMPEA acts as a stimulant primarily through sympathomimetic effects, exciting the central nervous system and enhancing alertness and energy levels in preclinical models. It produces central nervous system excitation comparable to amphetamines, though with reduced impact on locomotor activity. BMPEA and its analogs failed to produce significant changes in motor activity.

5. Scientific Evidence by Area

5.1 Cardiovascular and Blood Pressure Effects

Evidence type: Preclinical (animal) only. No controlled human clinical data exist.

The most rigorously characterized pharmacological effect of BMPEA is its capacity to elevate blood pressure. In rat models, subcutaneous administration of BMPEA at doses of 1–10 mg/kg produces dose-dependent increases in mean arterial blood pressure, with effects mediated by norepinephrine release via inhibition of the norepinephrine transporter (NET) in peripheral tissues. The 2019 NIDA study (Schindler et al., J Pharmacol Exp Ther, 369(3):328–336) remains the primary mechanistic reference document for this effect in preclinical models. More recent studies have shown that BMPEA can raise blood pressure and increase the risk of a cardiovascular event.

BMPEA is similar to amphetamine and may be illegally included in some supplements. It might increase blood pressure, heart rate, and also stimulate the brain. However, this effect profile is derived entirely from animal experiments and in vitro receptor assay data. No controlled human trials investigating the cardiovascular effects of BMPEA have been published.

5.2 Weight Loss and Obesity

Evidence type: None in humans. Putative mechanism only.

BMPEA is often added to products for weight loss and athletic performance. People use BMPEA for obesity, athletic performance, memory, and other purposes, but there is no good scientific evidence to support these uses. The rationale for its inclusion in weight-loss products is purely mechanistic — its structural similarity to amphetamine and sympathomimetic activity suggest a possible appetite-suppressing or thermogenic effect — but no human or animal efficacy studies specifically on weight loss or metabolic outcomes for BMPEA have been published in peer-reviewed sources.

5.3 Athletic Performance and Exercise

Evidence type: None in humans. Use is based on claimed stimulant properties; no efficacy studies exist.

Extracts of Acacia rigidula leaves are used in weight-loss products sold in vitamin shops and over the internet with little or no published data about their potential biological effects. The claimed rationale for BMPEA as an ergogenic aid derives entirely from its class membership as a sympathomimetic stimulant, not from human performance studies. Synthetic PEA analogs such as BMPEA are often found in dietary supplements despite regulations prohibiting their sale. PEA analogs are structurally related to amphetamine, and BMPEA and DEPEA have been shown to produce cardiovascular stimulation mimicking the effects of amphetamine. However, few studies have examined behavioral effects of BMPEA, DEPEA, and other PEA analogs.

5.4 Reinforcing Properties and Abuse Potential

Evidence type: Preclinical (rodent). No human data.

A 2022 study published in Psychopharmacology by researchers at the NIDA Intramural Research Program directly examined the reinforcing properties of BMPEA in an animal model. Researchers examined the reinforcing effects of α-ethylphenethylamine (AEPEA, 1 mg/kg/injection), DEPEA (1 mg/kg/injection), and BMPEA (3 mg/kg/injection) as compared to amphetamine (0.1 mg/kg/injection) using a fixed-ratio 1 self-administration paradigm in male rats. Rats were trained in self-administration chambers containing 2 nose-poke holes; a nose-poke response in the active hole delivered drug or saline, whereas a response in the inactive hole had no programmed consequence. Four groups of rats were initially trained for 10 days. Upon acquisition of drug self-administration, a dose-effect function was determined by training rats on 3 additional doses for 3 days each. A separate group of rats was trained with saline. Male rats self-administered each PEA analog and amphetamine, as shown by significant increases in active responses versus inactive responses.

BMPEA, AEPEA, and DEPEA interact with the dopamine transporter (DAT), the site of action implicated in the rewarding properties of stimulant drugs like cocaine and amphetamine. However, the compounds are unlikely to be heavily abused due to weak effects at DATs compared to classical stimulants. The absence of human data means no definitive conclusions about abuse liability in humans can be drawn from these preclinical findings alone.

5.5 Neurological and Cognitive Claims

Evidence type: None. No human or animal studies on cognition for BMPEA specifically.

BMPEA is sometimes marketed as a cognitive enhancer. BMPEA has gained attention as an ingredient in various nutritional supplements, particularly those marketed for energy, weight loss, or cognitive enhancement. No peer-reviewed studies examining cognitive outcomes attributable to BMPEA in either human participants or animal models have been located in the literature. This claimed application lacks any evidentiary basis in the published scientific record.

5.6 Adverse Event: Hemorrhagic Stroke (Case Report)

Evidence type: Single case report (human). Published in a peer-reviewed journal.

The most clinically significant human-level evidence concerning BMPEA involves a case report published in the Annals of Internal Medicine (2015) by Cohen, Zeijlon, Nardin, et al. The report describes a case of hemorrhagic stroke probably caused by exercise combined with BMPEA: a 53-year-old woman presented with one day of numbness and clumsiness in her left hand, reporting the sudden onset of symptoms 45 minutes after beginning a vigorous exercise routine she had performed several times weekly for years.

After initial reporting, the Jacked Power supplement consumed by the woman was analyzed and found to contain 290 mg of BMPEA per dose. The reporting physicians concluded that "exercise combined with BMPEA probably caused this patient's stroke." BMPEA was the only unlabeled pharmaceutical or drug found; neither BMPEA nor Acacia rigidula was listed on the supplement label.

When she sought medical care, the patient's blood pressure was elevated and a CT scan of her head showed a 2-cm hemorrhage in the right parietal lobe of her brain. MRI of the brain revealed the hemorrhage, with no underlying abnormalities. Cerebral angiography showed no evidence of vasculitis, aneurysm, or other vascular malformation. Blood pressure normalized after the woman was admitted to the hospital and remained normal. She was discharged after 5 days with minor residual sensory symptoms.

This case report is the first to suggest a connection between BMPEA and exercise-induced stroke. The limitation of this evidence is that it represents a single case report and cannot establish causation; however, the mechanistic plausibility (BMPEA-induced pressor effect synergizing with exercise-induced blood pressure elevation) has been noted by the authors and independent researchers.

6. Body Systems and Health Areas Associated with BMPEA

Cardiovascular System

BMPEA is possibly unsafe when taken by mouth. It has stimulant effects that might cause serious heart-related side effects, such as stroke and heart attack. BMPEA has stimulant effects; it can increase blood pressure. Taking BMPEA might make high blood pressure worse. These effects are mediated by peripheral NET-driven norepinephrine release, producing arterial constriction and elevated systolic and diastolic pressure.

Central Nervous System

BMPEA is a human TAAR1 agonist and acts as a substrate at central monoamine transporters, though its CNS stimulant effects appear weaker than those of amphetamine. BMPEA acts as a stimulant primarily through sympathomimetic effects, exciting the central nervous system and enhancing alertness and energy levels. In preclinical models, it produces central nervous system excitation comparable to amphetamines, though with reduced impact on locomotor activity.

Musculoskeletal/Performance System

BMPEA has been marketed for athletic performance, but no evidence supports ergogenic efficacy. Exposure to the supplement additive BMPEA has been linked with serious cardiovascular complications in human users, including hemorrhagic stroke. The combination of BMPEA-induced pressor effects and the hemodynamic demands of vigorous exercise may increase vascular risk.

7. Regulatory Status

United States Food and Drug Administration (FDA)

According to the US FDA, BMPEA does not meet the definition of a dietary supplement. The Federal Food, Drug, and Cosmetic Act defines a dietary ingredient as a vitamin; mineral; herb or other botanical; amino acid; dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of the preceding substances. BMPEA is none of these, rendering misbranded any products that declare BMPEA as a dietary supplement ingredient.

The US FDA concluded that products containing BMPEA were adulterated and banned their sale in 2015. The FDA issued notices about the use of DMBA and BMPEA in 2015. However, enforcement has been limited. Despite US Food and Drug Administration warning letters, BMPEA remains present in dietary supplements.

A 2017 follow-up study (published in JAMA Internal Medicine) examined continued availability and stimulant content of the same supplements that had been analyzed in 2014. Of the 21 brands of supplements analyzed in 2014, a total of 12 brands (57%) were still available for purchase in 2017. Of the 12 supplements purchased in 2017, a total of 9 (75%) contained at least 1 of the 4 stimulants subject to FDA notices, and 6 (50%) contained 2 or more.

World Anti-Doping Agency (WADA)

Beta-methylphenethylamine (BMPEA) was added as an example to the WADA Prohibited List. This stimulant is not a legitimate medication or dietary ingredient, but it can be found unlawfully in dietary supplements. It is a positional isomer of amphetamine, and based on this structural similarity, it is classified as a stimulant by WADA. Detection of BMPEA or amphetamine in a urine sample collected in competition constitutes a doping offense and results in sanctions against the athlete.

In the forensic field, unequivocal identification of amphetamine in a mixture of its positional isomers and structurally related compounds is of critical importance; the latter substances are often not controlled by public law, and their manufacturing, distribution, and use are legal in many jurisdictions. An ultra-performance liquid chromatography–tandem mass spectrometric (UPLC/MS/MS) analytical procedure enabling discrimination between amphetamine and BMPEA was elaborated and successfully applied to anti-doping urine samples, leading to the report of the first adverse analytical finding regarding BMPEA use.

Operation Supplement Safety (OPSS) / Military Guidance

BMPEA is an unapproved amphetamine-like substance that has been appearing in some dietary supplement products. The US Department of Defense's Operation Supplement Safety (OPSS) program has flagged BMPEA as a prohibited ingredient, citing its unapproved status and cardiovascular risk profile.

8. Prevalence of Adulteration: Key Surveillance Studies

Two independent analytical surveillance studies form the primary evidence base for understanding the scale of BMPEA adulteration in the supplement market.

FDA Study (2013–2014, published in Journal of Pharmaceutical and Biomedical Analysis): In chemical investigations on authenticated A. rigidula plant material, FDA researchers established a rapid LC-MS/MS method. The study revealed significant differences in the amine profiles of authenticated plant materials and dietary supplements. β-Methylphenethylamine, described as a non-natural compound, was found in 9 of the 21 dietary supplement products at levels of 960–60,500 μg/g, while phenethylamine was found at levels of 710–171,620 μg/g.

Cohen et al. (2015, published in Drug Testing and Analysis): Cohen et al. found that 11 of the 21 supplements tested — including those manufactured by Hi-Tech — contained high doses of BMPEA, an amphetamine isomer which had been synthesized in the 1930s as a potential amphetamine alternative. Detected levels reached up to 94 mg per daily dose, high enough to suggest pharmacological activity. Because BMPEA was not listed on the labels, the authors called for regulatory action due to its potential cardiovascular and neuropsychiatric risks.

In 2015, 52% of supplements labeled as containing Acacia rigidula were found to contain BMPEA. Consumers following recommended maximum daily servings would consume a maximum of 94 mg of BMPEA per day. The 290 mg dose found in the Swedish "Jacked Power" product associated with the stroke case report substantially exceeded this figure.

9. Dosage Forms and Doses Reported in Studies

Because BMPEA has not been approved for human use and has never undergone formal clinical trials, no therapeutic dosage has been established. The following quantities are derived exclusively from surveillance analyses of commercial supplement products and from preclinical animal research:

β-Methylphenethylamine was found in supplement products at levels of 960–60,500 μg/g (i.e., approximately 1–60.5 mg per gram of supplement material).
In the 2015 Cohen et al. analysis, 52% of supplements labeled as containing Acacia rigidula contained BMPEA. Consumers following recommended maximum daily servings would consume a maximum of 94 mg of BMPEA per day.
The Jacked Power supplement, associated with the hemorrhagic stroke case, was found to contain 290 mg of BMPEA per dose.
Animal studies (preclinical only): In rat models, subcutaneous administration of BMPEA at doses of 1–10 mg/kg produced dose-dependent increases in mean arterial blood pressure.
In cardiovascular telemetry experiments, amphetamine was tested at 0.3–3.0 mg/kg (sc), while BMPEA, MPPA, and DMPPA were tested at 3.0 and 30 mg/kg (sc), producing significant increases in blood pressure.
In preclinical self-administration studies, BMPEA was tested at 3 mg/kg/injection in rats compared to amphetamine at 0.1 mg/kg/injection.

At this time there is not enough scientific information to determine an appropriate range of doses for BMPEA in humans.

10. Safety Considerations and Drug Interactions

General Safety Status

BMPEA is possibly unsafe when taken by mouth. It has stimulant effects that might cause serious heart-related side effects, such as stroke and heart attack. BMPEA is an unapproved amphetamine-like substance. It was first made in the 1930s as a possible replacement to amphetamine, although it never became a drug because no studies were performed on its safety in humans. More recent studies have shown that BMPEA can raise blood pressure and increase the risk of a cardiovascular event.

Specific High-Risk Populations

Pregnancy and breastfeeding: BMPEA is possibly unsafe to take by mouth during pregnancy and breastfeeding. It has stimulant effects that might cause serious side effects, such as stroke and heart attack.

Pre-existing hypertension: BMPEA has stimulant effects. It can increase blood pressure. Taking BMPEA might make high blood pressure worse.

Pre-surgical patients: BMPEA has stimulant effects and its interaction with anesthetic agents and the cardiovascular stress of surgery presents theoretical risks that have not been formally studied.

Athletes exercising vigorously: Supplemental use of β-methylphenethylamine is previously linked to haemorrhagic strokes in exercising individuals. The synergy between exercise-induced blood pressure elevation and BMPEA's pressor effects appears to be a particularly high-risk combination, as evidenced by the published case report.

Adverse Events Reported in Humans

There have been several reports of increased heart rate and heart palpitations in people taking products containing Acacia rigidula. There is one reported case of cardiac arrest. It is unclear whether these side effects were caused by Acacia rigidula or other stimulants in these products. The only event specifically attributable to a BMPEA-containing product in the peer-reviewed literature is the hemorrhagic stroke case described in Annals of Internal Medicine (2015).

Drug and Supplement Interactions

BMPEA might have stimulant effects. Taking it with other supplements with similar effects might increase the chance of side effects, including rapid heartbeat and high blood pressure. Examples of supplements with this effect include 1,3-DMAA, bitter orange, caffeine-containing products, DMHA, and ephedra. There are no known interactions with foods.

BMPEA has been identified in supplements alongside other prohibited stimulants, including deterenol, phenpromethamine (vonedrine), oxilofrine, octodrine, 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA), and higenamine. The potential for pharmacodynamic interaction when multiple such stimulants are co-ingested, as commonly occurs in multi-ingredient preworkout formulations, represents an additional and unstudied risk.

Analytical Confusion with Amphetamine

β-Methylphenethylamine is a positional isomer of amphetamine, and research has shown that it can be misidentified as amphetamine during LC-MS analysis. An independent GC-MS analysis was required to confirm the presence of β-methylphenethylamine and the absence of amphetamine in dietary supplements labeled as containing A. rigidula. This study demonstrates that confirmations by independent analytical methods are essential to verify findings of unusual or unexpected compounds in dietary supplements. This analytical ambiguity has medico-legal relevance in both clinical toxicology and anti-doping contexts.

11. Overall Evidence Summary

Relatively little information has been published about this substance. The totality of the available evidence establishes BMPEA as a synthetic, laboratory-produced compound with a defined pharmacological mechanism (peripheral NET substrate activity, TAAR1 agonism) that predicts cardiovascular risk, but for which no controlled human clinical trials on efficacy or safety have been conducted. People use BMPEA for obesity, athletic performance, memory, and other purposes, but there is no good scientific evidence to support these uses.

The strongest evidence available consists of: (1) in vitro receptor binding and transporter release assays characterizing mechanism of action; (2) in vivo rat telemetry studies demonstrating dose-dependent pressor effects; (3) one peer-reviewed case report associating BMPEA ingestion with hemorrhagic stroke in a human; and (4) analytical surveillance studies documenting its widespread, undisclosed presence in commercial supplements. All efficacy claims — for weight loss, athletic performance, or cognitive enhancement — remain without any evidentiary foundation in the published peer-reviewed literature.